Ipratropium bromide: are patients treated with optimal therapy?

A.B. Millar, A. Bush, H. Al-Hillawi, J. Goldman and D.M. Denison

Department of Lung Function, Brompton Hospital, London SW3, UK.

Summary: A double-blind crossover placebo controlled study was performed on 20 patients with stable chronic asthma, in order to obtain dose response data to ipratropium bromide (40, 80, 200 µg) given by metered dose inhaler. The use of the 200 µg dose gave a significantly greater peak effect and duration of action than the recommended standard therapeutic dose of 40 µg. There were marked individual variations in response to higher doses. Maximum response detected by spirometry occurred within 24 hours of inhalation, thus patients likely to gain clinical benefit are readily identified. The higher dose was well tolerated by most patients and may have clinical application in the treatment of patients who do not respond to the standard dose regime.

Introduction

Ipratropium bromide is widely used for the treatment of asthma and chronic airflow obstruction. The standard dose of 40 µg administered by metered dose inhaler has been shown to be effective in these diseases.1-3 It has also been used in a nebulised form4-6 and in combination with β2 agonists.7,8 More recent work has suggested that a greater and more prolonged response may be produced with higher doses.1,4,9 This study was intended to determine the dose response to ipratropium bromide and the clinical acceptability and benefit of higher than standard therapeutic doses.

Materials and methods

Twenty chronic stable asthmatics (4 male) took part in this study (mean age ± s.d., 51 ± 17 years). These patients were all known to demonstrate at least 20% reversibility in forced expiratory volume in 1 second (FEV₁) to salbutamol by inhalation and had no exacerbations of their asthma requiring therapeutic changes in the previous 6 months. All were competent users of metered dose inhalers. All were non-smokers. Their baseline forced expiratory volume (FEV) (mean ± s.d.% predicted) was 47 ± 16%. The subjects were each studied on four separate days. Each patient was assessed on arrival on each study day. Spirometry was performed using a dry wedge spirometer and the best of three readings was noted. No greater than 10% difference was accepted in baseline measurements between each day. All bronchodilator therapy was discontinued 12 hours prior to administration of the trial drug on each investigation day but those patients taking concomitant steroid therapy continued to do so. The subjects received in double blind random order one of the following via twice inhaled puffs from metered dose inhaler, (a) placebo; (b) 40 µg ipratropium bromide; (c) 80 µg ipratropium bromide; (d) 200 µg ipratropium bromide. The effects of the drug or placebo were assessed by measuring FEV₁ and forced vital capacity (FVC) at -5, 0, 5, 15, 30, 45, 90 and 120 minutes and hourly thereafter until 480 minutes post-inhalation. The pulse rate was noted at the time points above and blood pressure was noted at 0, 60, 120 and 480 minutes. The subjects were asked to volunteer any side effects. This trial was approved by the ethical committee.

The data were analysed using a 3-way, mixed model of variance. Duncan's multiple range test was used to examine any source of variation. Time to peak effect and area under the response curve were analysed. Analysis of area under the response curve allows data biased by unequal time intervals to be assessed.

Results

One patient withdrew due to nausea and vomiting whilst on the highest dose of ipratropium bromide and all the patients complained that the medication had an unpleasant taste. For the remaining 19 patients, there were no significant differences
between the baseline values for the 3 treatments or placebo. All three doses of ipratropium bromide produced a significant change in FEV₁ compared to placebo at each time point except at 8 hours, \( P < 0.05 \) (Figure 1). The FVC following all three doses of ipratropium bromide differed significantly from values after placebo up to 2 hours post-inhalation and up to 6 hours post-inhalation for the highest dose showing a very similar pattern to the FEV₁ shown in Figure 1. The 200 µg dose produced a significantly greater FEV₁ (\( P < 0.05 \)) than the 40 µg dose at all time points, and than the 80 µg dose at 0, 30, 90, 180, 360, and 420 minutes post-inhalation. The maximum FEV₁ obtained was significantly greater (\( P < 0.05 \)) for the 200 µg dose than the 40 µg dose though not the 80 µg dose. The greatest difference in the mean FEV₁ values at any one point was 100 ml. We also looked at individual data; in 16 patients there was less than 10% difference between any of the doses of ipratropium. In 3 patients there were greater than 10% differences in spirometry after 80 µg compared to 40 µg, and in 2 of them there was a further increase in spirometry of more than 10% with 200 µg. There were no significant differences in pulse or blood pressure at any time post-inhalation of ipratropium bromide compared to placebo.

Discussion

The role of atropine-like drugs as bronchodilators has been recognized since the seventeenth century. The efficacy of ipratropium bromide as a bronchodilator has been widely shown in both asthma and chronic airflow obstruction. The currently recommended therapeutic dose of this drug is two puffs of 20 µg each via a metered dose inhaler although Atrovent forte (40 µg/puff) is available. However, some studies have suggested that a higher dose may be beneficial in terms of duration and peak effect. A small but significant increase in the peak FEV₁ of bronchitis was shown after inhalation of a 120 µg dose and similar increase in asthmatics and bronchitics using an 80 µg dose comparing these to the standard regime but without placebo control. Hockley and Johnson documented a small increase in FEV₁ and FVC of chronic asthmatics using 40 µg and 100 µg doses in placebo controlled study.

In the present study three patients showed an increase in FEV₁ of greater than 10% after inhalation of 80 µg and 2 patients showed sequential increases of greater than 10% with 200 µg compared to 80 µg. All the subjects noted an unpleasant taste with the three drug doses compared to placebo. One patient had to withdraw because of headache and nausea whilst taking the highest dose. However, no abnormality was found on clinical examination and the significance of this incident is questionable.

The data presented confirm that a higher dose than that recommended, of 200 µg, produced a significantly greater peak effect and duration than either placebo or the standard dose of 40 µg. However, as in previous studies the actual changes in spirometry were in the order of 100 ml and the clinical significance of such differences remains unclear.

We conclude that ipratropium bromide is an effective bronchodilator agent which produces a greater effect on spirometry when given in higher doses than those currently used most widely. In some patients this may be of clinical significance and these individuals could be identified by repeated spirometry over the initial 2 hours post-inhalation of such therapy.

Acknowledgements

We would like to thank Boehringer Ingelheim for financial support of this study and Miss Annette Skinner for her expert secretarial assistance.

References


